JP2008537725A - 部分的ドーパミン−ｄ２受容体作動性とセロトニン再摂取阻害の組み合わせを示すフェニルピペラジン誘導体 - Google Patents

部分的ドーパミン−ｄ２受容体作動性とセロトニン再摂取阻害の組み合わせを示すフェニルピペラジン誘導体 Download PDF

Info

Publication number
JP2008537725A
JP2008537725A JP2007544898A JP2007544898A JP2008537725A JP 2008537725 A JP2008537725 A JP 2008537725A JP 2007544898 A JP2007544898 A JP 2007544898A JP 2007544898 A JP2007544898 A JP 2007544898A JP 2008537725 A JP2008537725 A JP 2008537725A
Authority
JP
Japan
Prior art keywords
mmol
scheme
alkyl
stage
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007544898A
Other languages
English (en)
Japanese (ja)
Inventor
フエーンストラ，ローロフ・ダブリユー
ストイト，アクセル
テルプストラ，ヤン−ウイレム
プラス−ラベス，マリア・エル
マクリーリー，アンドリユー・シー
バン・ブリート，ベルナルド・ジエイ
ヘセリンク，マイケ・ビー
クルゼ，コルネリス・ジー
バン・シヤレンブルク，グスターフ・ジエイ・エム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Healthcare Products BV
Original Assignee
Abbott Healthcare Products BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Healthcare Products BV filed Critical Abbott Healthcare Products BV
Publication of JP2008537725A publication Critical patent/JP2008537725A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Fats And Perfumes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2007544898A 2004-12-08 2005-12-06 部分的ドーパミン−ｄ２受容体作動性とセロトニン再摂取阻害の組み合わせを示すフェニルピペラジン誘導体 Withdrawn JP2008537725A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63407404P 2004-12-08 2004-12-08
EP04106394 2004-12-08
PCT/EP2005/056508 WO2006061379A1 (en) 2004-12-08 2005-12-06 Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition

Publications (1)

Publication Number Publication Date
JP2008537725A true JP2008537725A (ja) 2008-09-25

Family

ID=35744728

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2007544897A Withdrawn JP2008523031A (ja) 2004-12-08 2005-12-06 部分的ドーパミン−ｄ２受容体作動性とセロトニン再摂取阻害の組み合わせを示すフェニルピペラジン誘導体
JP2007544898A Withdrawn JP2008537725A (ja) 2004-12-08 2005-12-06 部分的ドーパミン−ｄ２受容体作動性とセロトニン再摂取阻害の組み合わせを示すフェニルピペラジン誘導体
JP2007544896A Withdrawn JP2008523030A (ja) 2004-12-08 2005-12-06 部分的ドーパミン−ｄ２受容体作動性とセロトニン再摂取阻害の組み合わせを示すフェニルピペラジン誘導体
JP2007544895A Withdrawn JP2008523029A (ja) 2004-12-08 2005-12-06 部分的ドーパミン−ｄ２受容体作動性とセロトニン再摂取阻害の組み合わせを示すアリールオキシエチルアミン誘導体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007544897A Withdrawn JP2008523031A (ja) 2004-12-08 2005-12-06 部分的ドーパミン−ｄ２受容体作動性とセロトニン再摂取阻害の組み合わせを示すフェニルピペラジン誘導体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2007544896A Withdrawn JP2008523030A (ja) 2004-12-08 2005-12-06 部分的ドーパミン−ｄ２受容体作動性とセロトニン再摂取阻害の組み合わせを示すフェニルピペラジン誘導体
JP2007544895A Withdrawn JP2008523029A (ja) 2004-12-08 2005-12-06 部分的ドーパミン−ｄ２受容体作動性とセロトニン再摂取阻害の組み合わせを示すアリールオキシエチルアミン誘導体

Country Status (18)

Country Link
EP (4) EP1827427B1 (enExample)
JP (4) JP2008523031A (enExample)
KR (4) KR20070085959A (enExample)
AT (2) ATE401883T1 (enExample)
AU (4) AU2005313390A1 (enExample)
BR (1) BRPI0518613A2 (enExample)
CA (4) CA2587202A1 (enExample)
DE (2) DE602005008471D1 (enExample)
DK (2) DK1824479T3 (enExample)
ES (2) ES2311245T3 (enExample)
HR (2) HRP20090015T3 (enExample)
IL (4) IL183061A0 (enExample)
NO (4) NO20072981L (enExample)
PL (2) PL1827427T3 (enExample)
PT (2) PT1824479E (enExample)
RU (4) RU2007125660A (enExample)
SI (2) SI1824479T1 (enExample)
WO (4) WO2006061377A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059227A1 (es) * 2006-01-30 2008-03-19 Speedel Experimenta Ag Proceso para la preparacion de compuestos organicos
US8063062B2 (en) 2006-12-20 2011-11-22 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid-CB1 antagonism and acetylcholinesterase inhibition
US8138174B2 (en) 2007-01-10 2012-03-20 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid CB1 antagonism and serotonin reuptake inhibition
CA2671554A1 (en) * 2007-01-10 2008-07-17 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition
JP2010525013A (ja) * 2007-04-23 2010-07-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 高速解離性ドパミン２受容体アンタゴニストとしてのピリジン誘導体
WO2008128996A1 (en) * 2007-04-23 2008-10-30 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
KR20100016620A (ko) * 2007-04-23 2010-02-12 얀센 파마슈티카 엔.브이. 속해리성 도파민 2 수용체 길항제로서의 4-알콕시피리다진 유도체
CN103360342B (zh) * 2012-04-09 2015-12-16 江苏恩华药业股份有限公司 3-氰基苯胺烷基芳基哌嗪衍生物及在制备药物中的应用
CN103570698B (zh) * 2012-08-01 2016-08-03 江苏恩华药业股份有限公司 用于制备维拉佐酮的化合物及其中间体和应用
ITMI20130392A1 (it) * 2013-03-15 2014-09-16 Dipharma Francis Srl Sintesi di un inibitore della ricaptazione della serotonina
EP3010586A1 (en) 2013-06-21 2016-04-27 Lupin Limited Substituted heterocyclic compounds as crac modulators
US9790231B2 (en) 2013-06-24 2017-10-17 Lupin Limited Chromane and chromene derivatives and their use as CRAC modulators
CN104337812B (zh) 2013-07-29 2018-09-14 广东东阳光药业有限公司 取代的杂芳基化合物及其使用方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692264B1 (fr) * 1992-06-12 1994-08-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
EP0900792B1 (en) * 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
CN1304403A (zh) * 1998-04-08 2001-07-18 美国家用产品公司 用于治疗抑郁症的n－芳氧基乙基－吲哚基－烷基胺(5－ht1a受体活化剂)
CA2335711A1 (en) * 1998-06-19 1999-12-29 Ivan Mikkelsen 4,5,6 and 7-indole and indoline derivatives, their preparation and use
AR022303A1 (es) * 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
WO2001014330A2 (en) * 1999-08-23 2001-03-01 Solvay Pharmaceuticals B.V. Phenylpiperazines as serotonin reuptake inhibitors
CN1723209A (zh) * 2002-12-10 2006-01-18 默克专利有限公司 吲哚衍生物以及它们作为5－ht配体的应用

Also Published As

Publication number Publication date
WO2006061378A1 (en) 2006-06-15
JP2008523029A (ja) 2008-07-03
CA2587202A1 (en) 2006-06-15
IL183061A0 (en) 2007-09-20
CA2587357A1 (en) 2006-06-15
NO20072974L (no) 2007-08-23
DK1824479T3 (da) 2009-03-09
WO2006061377A1 (en) 2006-06-15
EP1824479B1 (en) 2008-11-05
KR20070085975A (ko) 2007-08-27
ATE401883T1 (de) 2008-08-15
IL183064A0 (en) 2007-09-20
DE602005008471D1 (de) 2008-09-04
NO20072981L (no) 2007-09-05
BRPI0518613A2 (pt) 2008-11-25
CA2587381A1 (en) 2006-06-15
RU2007125661A (ru) 2009-01-20
KR20070085959A (ko) 2007-08-27
JP2008523031A (ja) 2008-07-03
PT1824479E (pt) 2009-01-30
DE602005010902D1 (de) 2008-12-18
EP1827426A1 (en) 2007-09-05
AU2005313390A1 (en) 2006-06-15
KR20070085988A (ko) 2007-08-27
AU2005313312A1 (en) 2006-06-15
ES2317335T3 (es) 2009-04-16
DK1827427T3 (da) 2008-11-24
HRP20080538T3 (en) 2008-12-31
IL183062A0 (en) 2007-09-20
NO20072969L (no) 2007-08-31
SI1824479T1 (sl) 2009-04-30
RU2007125658A (ru) 2009-01-20
WO2006061379A1 (en) 2006-06-15
EP1824480A1 (en) 2007-08-29
NO20072977L (no) 2007-09-05
CA2587559A1 (en) 2006-06-15
RU2007125659A (ru) 2009-01-20
PL1827427T3 (pl) 2009-01-30
ES2311245T3 (es) 2009-02-01
SI1827427T1 (sl) 2008-12-31
HRP20090015T3 (en) 2009-02-28
WO2006061376A1 (en) 2006-06-15
EP1827427A1 (en) 2007-09-05
IL183063A0 (en) 2007-09-20
EP1827427B1 (en) 2008-07-23
AU2005313311A1 (en) 2006-06-15
KR20070085916A (ko) 2007-08-27
ATE413173T1 (de) 2008-11-15
JP2008523030A (ja) 2008-07-03
EP1824479A1 (en) 2007-08-29
PL1824479T3 (pl) 2009-04-30
PT1827427E (pt) 2008-11-03
RU2007125660A (ru) 2009-01-20
AU2005313391A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
US5834493A (en) Indole derivatives as 5-HT1A and/or 5-HT2 ligands
US20060293313A1 (en) New phenylpiperazines
JP2008537725A (ja) 部分的ドーパミン−ｄ２受容体作動性とセロトニン再摂取阻害の組み合わせを示すフェニルピペラジン誘導体
US8101619B2 (en) Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
US8106044B2 (en) 8-{4-[3-(5-fluoro-1H-indol-3-yl)-propyl]-piperazin-1-yl}-2-methyl-4H-benzo[1,4]oxazin-3-one mesylate with high affinity for the dopamine D2 receptor and the serotonin reuptake site
AU2005313388A1 (en) Benzdioxane piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
US20070142397A2 (en) Phenypiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition
US7371769B2 (en) Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
CN101072560A (zh) 具有部分多巴胺－d2受体激动作用与血清素再摄取抑制作用组合的苯基哌嗪衍生物
HK1109343A (en) Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition
CA2587936A1 (en) Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-d2 receptors and serotonin reuptake sites
HK1113903A (en) Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition
HK1109622A (en) Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-d2 receptors and serotonin reuptake sites
HK1109571A (en) Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081205

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090814